Patents by Inventor David B. Agus
David B. Agus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240069026Abstract: A method assessing tissue morphology using machine learning includes a step of training a machine learnable device to predict the status of a diagnostic feature in stained tissue samples. The machine learnable device is trained with a characterized set of digital images of stained tissue samples. Each digital image of the characterized set has a known status for the diagnostic feature and an extracted feature map provides values for a extracted feature over an associated 2-dimensional grid of spatial locations. A step of inputting the set of extracted feature maps is inputted into the machine learnable device to form associations therein between the set of extracted feature maps to and the known status for the diagnostic feature to form a trained machine learnable device. The status for the diagnostic feature of a stained tissue sample of unknown status for the diagnostic feature is predicted from the trained machine learnable device.Type: ApplicationFiled: November 7, 2023Publication date: February 29, 2024Applicant: University of Southern CaliforniaInventors: David B. AGUS, Paul Thomas MACKLIN, Rishi Raghav RAWAT, Daniel Lee RUDERMAN
-
Patent number: 11835524Abstract: A method assessing tissue morphology using machine learning includes a step of training a machine learnable device to predict the status of a diagnostic feature in stained tissue samples. The machine learnable device is trained with a characterized set of digital images of stained tissue samples. Each digital image of the characterized set has a known status for the diagnostic feature and an extracted feature map provides values for a extracted feature over an associated 2-dimensional grid of spatial locations. A step of inputting the set of extracted feature maps is inputted into the machine learnable device to form associations therein between the set of extracted feature maps to and the known status for the diagnostic feature to form a trained machine learnable device. The status for the diagnostic feature of a stained tissue sample of unknown status for the diagnostic feature is predicted from the trained machine learnable device.Type: GrantFiled: March 6, 2018Date of Patent: December 5, 2023Assignee: University of Southern CaliforniaInventors: David B. Agus, Paul Thomas Macklin, Rishi Raghav Rawat, Daniel Lee Ruderman
-
Publication number: 20230133119Abstract: Herein is reported a class of chiral compounds with paradoxical effects on the androgen receptor (AR). The (R)-enantiomers behave like classical anti-androgens while the (S)-enantiomers activate AR signaling. In castration-resistant prostate cancer, the change during the course of therapy to growth in the presence of AR targeted therapeutics, a harbinger of progression to lethal disease, is commonly attributed to acquired mutations of the AR-ligand binding domain. This is the first report of an antagonist—agonist duality solely due to structural enantiomerism, without any modification to the AR binding site.Type: ApplicationFiled: March 22, 2021Publication date: May 4, 2023Applicant: University of Southern CaliforniaInventors: Charles E. McKenna, David B. Agus
-
Patent number: 10867706Abstract: Described herein are methods and systems to measure dynamics of disease progression, including cancer growth and response, at multiple scales by multiple techniques on the same biologic system. Methods and systems according to the invention permit personalized virtual disease models. Moreover, the invention allows for the integration of previously unconnected data points into an in silico disease model, providing for the prediction of disease progression with and without therapeutic intervention.Type: GrantFiled: August 13, 2015Date of Patent: December 15, 2020Assignees: APPLIED INVENTION, LLC, UNIVERSITY OF SOUTHERN CALIFORNIAInventors: William Daniel Hillis, David B. Agus
-
Publication number: 20200388028Abstract: A method assessing tissue morphology using machine learning includes a step of training a machine learnable device to predict the status of a diagnostic feature in stained tissue samples. The machine learnable device is trained with a characterized set of digital images of stained tissue samples. Each digital image of the characterized set has a known status for the diagnostic feature and an extracted feature map provides values for a extracted feature over an associated 2-dimensional grid of spatial locations. A step of inputting the set of extracted feature maps is inputted into the machine learnable device to form associations therein between the set of extracted feature maps to and the known status for the diagnostic feature to form a trained machine learnable device. The status for the diagnostic feature of a stained tissue sample of unknown status for the diagnostic feature is predicted from the trained machine learnable device.Type: ApplicationFiled: March 6, 2018Publication date: December 10, 2020Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: David B. AGUS, Paul Thomas MACKLIN, Rishi Raghav RAWAT, Daniel Lee RUDERMAN
-
Publication number: 20160103971Abstract: Described herein are methods and systems to measure dynamics of disease progression, including cancer growth and response, at multiple scales by multiple techniques on the same biologic system. Methods and systems according to the invention permit personalized virtual disease models. Moreover, the invention allows for the integration of previously unconnected data points into an in silico disease model, providing for the prediction of disease progression with and without therapeutic intervention.Type: ApplicationFiled: August 13, 2015Publication date: April 14, 2016Inventors: W. Daniel Hillis, David B. Agus
-
Patent number: 9141756Abstract: Described herein are methods and systems to measure dynamics of disease progression, including cancer growth and response, at multiple scales by multiple techniques on the same biologic system. Methods and systems according to the invention permit personalized virtual disease models. Moreover, the invention allows for the integration of previously unconnected data points into an in silico disease model, providing for the prediction of disease progression with and without therapeutic intervention.Type: GrantFiled: July 20, 2011Date of Patent: September 22, 2015Assignees: University of Southern California, Applied Invention, LLCInventors: W. Daniel Hillis, David B. Agus
-
Patent number: 8333964Abstract: The present application describes the use of ErbB antagonist, especially ErbB2 antibodies such as rhuMAb 2C4, for treating pain.Type: GrantFiled: November 29, 2010Date of Patent: December 18, 2012Assignee: Genentech, Inc.Inventor: David B. Agus
-
Patent number: 7955810Abstract: This invention relates to methods and kits for positive selection of species of interest based on peptide/protein sequence from a biological sample. The species of interest may be proteins and/or peptides of interest which may be placed through a mass spectrometer to obtain a blood peptide/protein signature. The blood peptide/protein signature may be used in proteomic analysis. The techniques include but are not limited to the use of collectors comprising nucleic acid molecules to extract a composition that has a lower concentration of a high abundance species of interest from a sample. This limits the level of influence that any collectors species may have on the results of a mass spectra.Type: GrantFiled: November 30, 2007Date of Patent: June 7, 2011Assignees: Cedars-Sinai Medical Center, Applied Proteomics, Inc.Inventors: David B. Agus, William Daniel Hillis
-
Publication number: 20110064737Abstract: The present application describes the use of ErbB antagonist, especially ErbB2 antibodies such as rhuMAb 2C4, for treating pain.Type: ApplicationFiled: November 29, 2010Publication date: March 17, 2011Inventor: DAVID B. AGUS
-
Publication number: 20100297152Abstract: Described herein are genes whose expression are up-regulated or down-regulated in prostate cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant prostate cancer cells. Related methods and compositions that can be used for diagnosis and treatment of prostate cancer are disclosed. Also described herein are methods that can be used to identify modulators of prostate cancer.Type: ApplicationFiled: December 30, 2008Publication date: November 25, 2010Applicant: CEDARS-SINAI MEDICAL CENTERInventor: David B. Agus
-
Patent number: 7816647Abstract: The present invention relates to a system and method for mass spectrometry (100) that allows for bi-directional introduction of collections of charged particles into the magnetic field of a mass spectrometer. More particularly, the present invention includes a system for mass spectrometry (100) (e.g., an FTMS mass spectrometer) with a cylindrical magnet (101) configured to receive and measure the cyclotron frequencies (104) of charged particles that are introduced (102, 103) into the cylindrical magnet (101) from either of the two axial ends thereof. Methods of the invention relate to performing mass spectrometry analysis on collections of charged particles that are introduced (102, 103), serially, simultaneously or both, into a cylindrical magnet (101) from opposing axial ends thereof. The present invention exhibits significantly increased magnet throughput relative to currently available devices, by allowing flow in the opposite direction to a second detector, e.g.Type: GrantFiled: February 28, 2006Date of Patent: October 19, 2010Assignee: Cedars-Sinai Medical CenterInventor: David B. Agus
-
Patent number: 7803546Abstract: Described herein are methods for treating cancer and other disease conditions in individuals who have either developed a resistance to conventional tyrosine kinase inhibitor (TKI) therapy or who are non-responsive ab initio to conventional TKI therapy. In various embodiments, the methods include administering to a patient a resistance-surmounting quantity of a TKI on a weekly or semi-weekly basis. Alternate embodiments of the present invention include a diagnostic method for assessing an individual's probability of being resistant to TKI therapy, based upon an expression level of epithelial membrane protein-1 (EMP-1); one of the genes believed to be responsible for TKI resistance. The methods of the present invention may be particularly useful in the treatment of lung, breast, prostate, ovarian, brain and colon cancers. The methods of the present invention may be effective in blocking the HER-2 kinase domain either in addition to or in lieu of blocking the EGFR kinase domain.Type: GrantFiled: February 23, 2007Date of Patent: September 28, 2010Assignee: Cedars-Sinai Medical CenterInventor: David B. Agus
-
Publication number: 20100055697Abstract: This invention relates to methods and kits for positive selection of species of interest based on peptide/protein sequence from a biological sample. The species of interest may be proteins and/or peptides of interest which may be placed through a mass spectrometer to obtain a blood peptide/protein signature. The blood peptide/protein signature may be used in proteomic analysis. The techniques include but are not limited to the use of collectors comprising nucleic acid molecules to extract a composition that has a lower concentration of a high abundance species of interest from a sample. This limits the level of influence that any collectors species may have on the results of a mass spectra.Type: ApplicationFiled: November 30, 2007Publication date: March 4, 2010Applicants: CEDARS-SINAI MEDICAL CENTER, APPLIED MINDS, INC.Inventors: David B. Agus, William Daniel Hillis
-
Publication number: 20090008546Abstract: The present invention relates to a system and method for mass spectrometry (100) that allows for bi-directional introduction of collections of charged particles into the magnetic field of a mass spectrometer. More particularly, the present invention includes a system for mass spectrometry (100) (e.g., an FTMS mass spectrometer) with a cylindrical magnet (101) configured to receive and measure the cyclotron frequencies (104) of charged particles that are introduced (102, 103) into the cylindrical magnet (101) from eith of the two axial ends thereof. Methods of the invention relate to performing mass spectrometry analysis on collections of charged particles that are introduced (102, 103), serially, simultaneously or both, into a cylindrical magnet (101) from opposing axial ends thereof. The present invention exhibits significantly increased magnet throughput relative to currently available devices, by allowing flow in the opposite direction to a second detector, e.g.Type: ApplicationFiled: February 28, 2006Publication date: January 8, 2009Applicant: CEDARS-SINAI MEDICAL CENTERInventor: David B. Agus
-
Patent number: 7425565Abstract: Disclosed herein is a method for treating and preventing prostate cancer, and particularly androgen-independent prostate cancer, the method including administering to a mammal a benzothiopene having the formula or pharmaceutically acceptable salts or prodrugs thereof, wherein R and R1 are each independently selected from the group consisting of hydrogen, —COR2, —COR3, and R4; R2 is selected from the group consisting of hydrogen, C1-C14 alkyl, C1-C3 chloroalkyl, C1-C3 fluoroalkyl, C5-C7 cycloalkyl, C1-C4 alkoxy, and phenyl; R3 is phenyl with at least one substitution selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, hydroxy, nitro, chloro, fluoro, trichloromethyl, and trifluoromethyl; R4 is selected from the group consisting of C1-C4 alkyl, C5-C7 cycloalkyl, and benzyl; and R5 is selected from the group consisting of oxygen and —C?O. The method may further include the administration of an estrogen lowering drug to enhance efficacy of the compound of the present invention.Type: GrantFiled: July 23, 2003Date of Patent: September 16, 2008Assignee: Cedars-Sinai Medical CenterInventor: David B. Agus
-
Patent number: 7384940Abstract: Described herein are methods for treating cancer and other disease conditions in individuals who have either developed a resistance to conventional tyrosine kinase inhibitor (TKI) therapy or who are non-responsive ab initio to conventional TKI therapy. In various embodiments, the methods include administering to a patient a resistance-surmounting quantity of a TKI on a weekly or semi-weekly basis. Alternate embodiments of the present invention include a diagnostic method for assessing an individual's probability of being resistant to TKI therapy, based upon an expression level of epithelial membrane protein-1 (EMP-1); one of the genes believed to be responsible for TKI resistance. The methods of the present invention may be particularly useful in the treatment of lung, breast, prostate, ovarian, brain and colon cancers. The methods of the present invention may be effective in blocking the HER-2 kinase domain either in addition to or in lieu of blocking the EGFR kinase domain.Type: GrantFiled: June 4, 2003Date of Patent: June 10, 2008Assignee: Cedars-Sinai Medical CenterInventor: David B. Agus
-
Publication number: 20080038194Abstract: The present invention relates to modification of isotope ratios in peptides and polypeptides as an alternative to full isotopic exchange for coding in proteomics. Subtle modification of isotope ratio does not compromise protein identification experiments and can thus provide elemental composition data for accurate isotope ratio decoding. Application of subtle modification of isotope ratio proteomics (SMIRP) offers a convenient approach to in vivo isotope coding.Type: ApplicationFiled: January 13, 2005Publication date: February 14, 2008Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Julian P. Whitelegge, David B. Agus, Jonathan Katz
-
Publication number: 20040132776Abstract: Disclosed herein is a method for treating and preventing prostate cancer, and particularly androgen-independent prostate cancer, the method including administering to a mammal a benzothiopene having the formula 1Type: ApplicationFiled: July 23, 2003Publication date: July 8, 2004Applicant: CEDARS-SINAI MEDICAL CENTERInventor: David B. Agus
-
Publication number: 20040096896Abstract: Systems and methods of diagnosing and/or treating physiologic conditions based upon pattern recognition of serum protein profiles are provided. Mass spectrometry or other conventional techniques for creating a profile of serum proteins is employed, and a patient's profile is thereafter digitized for computational analysis. A pattern recognition algorithm is implemented to determine a degree of similarity between the patient's profile and other profiles stored in a database along with information describing the pathologic state of the individuals from whom such data was obtained. The degree of similarity may provide an indication of, for example, the way in which the patient may react to a particular clinical treatment or their predisposition to a particular disease condition. The methods and system of the present invention may be used to monitor the dynamic progression of disease pathology in a patient, and may be implemented via a computer network.Type: ApplicationFiled: November 14, 2002Publication date: May 20, 2004Applicant: CEDARS-SINAI MEDICAL CENTERInventors: David B. Agus, Mark D. Kvamme